ENSC stock forecast, quote, news & analysis
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs... Show more
Ensysce Biosciences (ENSC) Stock Analysis: Clinical-Stage Pain Pipeline in Focus After the Cy Biopharma Merger
Key Takeaways
- Ensysce Biosciences (ENSC) traded near $0.42 in late October 2026, roughly flat versus a month earlier despite a sharp mid-month spike and pullback.
- The company completed its acquisition of Cy Biopharma on August 5, 2026, adding the CY200 severe-pain candidate and reshaping its clinical pipeline.
- Cantor Fitzgerald initiated coverage with an Overweight rating and a $2 price target, citing the strategic value of the Cy Biopharma combination.
- As a clinical-stage, small-cap biotechnology company, ENSC carries elevated risk, with a market capitalization near $8 million and weekly price swings well above market norms.
- A registration to sell up to roughly 433.9 million common shares on behalf of selling stockholders remains a key dilution overhang investors are monitoring.
- For more detail on valuation and catalysts, explore Ensysce Biosciences' Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading bots are positioning around this ticker and others.
Current Market Snapshot
Ensysce Biosciences stock closed near $0.42 at the end of October 2026, placing the shares firmly in penny-stock territory and reflecting a market capitalization of roughly $8 million. Over the trailing 30 days, the stock was essentially unchanged on a net basis, even though intra-period trading was notably volatile, with the price spiking above $0.59 in mid-October before retracing.
The 52-week range of approximately $0.23 to $2.23 underscores how dramatically sentiment around this micro-cap name can shift. Trailing twelve-month revenue was about $4.5 million, while the company continued to report a net loss. These figures highlight the speculative, event-driven nature of the stock, where clinical and corporate milestones typically matter more than near-term fundamentals.
Ensysce Biosciences (ENSC) Business Overview and Competitive Position
Ensysce Biosciences is a clinical-stage biopharmaceutical company based in La Jolla, California, focused on developing safer prescription drugs for severe pain. Its proprietary Trypsin Activated Abuse Protection (TAAP) platform is designed to release an active drug only under specific physiological conditions, while its Multi-Pill Abuse Resistance (MPAR) technology is intended to reduce overdose risk. The lead candidate, PF614, is a TAAP oxycodone prodrug being studied for severe or chronic pain, with PF614-MPAR combining PF614 and nafamostat for overdose protection.
The company's portfolio also includes amphetamine prodrugs for attention deficit hyperactivity disorder and candidates targeting opioid use disorder. The August 2026 acquisition of Cy Biopharma expanded the pipeline, bringing in CY200 and related severe-pain assets. Investors follow ENSC primarily for its differentiated approach to opioid safety and the potential value of its clinical milestones, while recognizing that the company remains pre-commercial with a limited cash runway typical of early-stage biotechnology firms.
Recent Developments Driving ENSC
The most significant development of the past month was corporate rather than clinical. Ensysce completed its merger with Cy Biopharma on August 5, 2026, a transaction the company has framed as a way to broaden its severe-pain pipeline. Following the deal, Cantor Fitzgerald initiated coverage of ENSC with an Overweight rating and a $2 price target, a notable vote of confidence from the sell-side for a stock trading below $0.50.
Ensysce also stepped up investor outreach, with management participating in the Family Office Summit in Dubai in mid-October as it sought to build awareness of CY200 and its broader pipeline. At the same time, a registration statement covering the potential resale of up to roughly 433.9 million common shares for selling stockholders introduced a meaningful supply overhang, contributing to choppy trading and the pullback from October's intra-month highs. These competing forces, strategic optimism against financing-related dilution, largely explain the stock's wide swings.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that monitor thousands of tickers across the market. While Tickeron offers hundreds of these automated strategies, only the top-performing and most relevant bots are surfaced in this section, helping traders filter through the noise. The bots vary widely in strategy, timeframe, and performance metrics, ranging from short-term momentum approaches to longer-horizon trend models. For investors tracking volatile micro-cap names like Ensysce Biosciences, reviewing how these systems are positioned can add a data-driven perspective to traditional research. Visitors can browse the section to explore which AI robots are currently drawing attention across the market.
2026 Outlook and What Investors Should Watch
Heading into the remainder of 2026, the key items for ENSC investors center on execution and financing. The company's next earnings report, expected around mid-November 2026, will be closely watched for updates on cash position, operating expenses, and any commentary on the CY200 program acquired from Cy Biopharma. Clinical progress on PF614, PF614-MPAR, and the newly added pain assets will likely remain the primary long-term value drivers.
Capital markets activity is equally important. Any additional equity raises, conversions of preferred stock issued in the merger, or follow-on offerings could pressure the share price, given the already significant share count. Regulatory milestones and any further analyst initiation or rating changes may also shape sentiment. Investors should monitor these catalysts without treating them as guarantees of price direction, given the inherent risks of clinical-stage biotechnology.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for ENSC turns negative, indicating new downward trend
ENSC saw its Momentum Indicator move below the 0 level on October 23, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In 83 of the 90 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ENSC turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 42 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
ENSC moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ENSC crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENSC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ENSC broke above its upper Bollinger Band on October 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ENSC entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ENSC's RSI Oscillator exited the oversold zone, 38 of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for ENSC moved above the 200-day moving average on October 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +9.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where ENSC advanced for three days, in 159 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.181) is normal, around the industry mean (3.498). P/E Ratio (-0.128) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. ENSC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENSC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology